ResMed Inc. (RMD) — Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is modestly constructive — consensus is a manageable bar, the MatrixCare divestiture announced July 7 is the single biggest swing factor, and the market will focus on whether management can deliver a clean FY2027 outlook that absorbs the portfolio change while sustaining gross margin expansion.

Heading into Q4 FY2026, the bar for RMD looks achievable: consensus revenue of ~$1.46B implies ~8% YoY growth, broadly in line with the high-single-digit constant-currency trajectory management has guided to, and non-GAAP EPS consensus of ~$2.89 sits just below the $2.86 reported last quarter. The most significant development since the April 30 print is the July 7 announcement of the MatrixCare divestiture to Frazier Healthcare for $490M — a strategic portfolio sharpening that removes ~$220M in lower-margin RCS revenue and ~$55M in non-GAAP operating profit from the FY2027 base, with proceeds earmarked for an accelerated share repurchase program. Management's tone has been consistently confident: the Q3 call introduced the Noctrix acquisition (closed June 1), the Oura Ring partnership (May 19), and an explicit commitment to >$800M in buybacks for FY2027, all signaling a management team leaning into capital return and portfolio quality rather than defensiveness. Estimate revisions have been essentially flat since the Q3 print — revenue and EPS estimates for Q4 FY2026 are nearly unchanged from the post-Q3 baseline — suggesting the street is neither chasing upside nor cutting numbers, which leaves the stock without a strong pre-print directional lean.

RMD has underperformed both IHI (+5.2%) and the S&P 500 (+7.1%) since the April 30 earnings, rising only ~4.8%, with the stock selling off sharply in late May/early June before recovering on the MatrixCare announcement. The key wildcard is FY2027 guidance: the market needs to see a credible framework that bridges the MatrixCare revenue hole (~$220M), absorbs ~$0.20 of Noctrix EPS dilution, and still delivers accelerating RCS growth and sustained gross margin expansion — if management threads that needle, the stock could re-rate; if the FY2027 outlook disappoints on any of those dimensions, the recent recovery could reverse.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar on both revenue (~$1.46B, +8% YoY) and non-GAAP EPS (~$2.89); gross margin is the bigger swing factor — continued expansion above the 61–63% FY2026 guidance band would be the clearest upside signal.

Table 1 — Q4 FY2026 Current Quarter Snapshot

Source: Visible Alpha consensus and actuals data. All figures in USD millions unless noted. Q4 FY2026 = fiscal quarter ending June 30, 2026. Q4 FY2025 = fiscal quarter ending June 30, 2025.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Top 2 KPIs: Net Revenue & Non-GAAP Diluted EPS

Pattern: RMD has beaten or matched revenue consensus in 7 of the last 8 quarters and beaten non-GAAP EPS in 7 of 8, with EPS beats typically driven by gross margin outperformance — a consistent pattern that sets a modest but achievable bar heading into Q4 FY2026. Source: Visible Alpha.

3. Guidance & Commentary Evolution

Key Takeaway: Management's posture has shifted more constructive since the April 30 Q3 print — the MatrixCare divestiture (announced July 7) is the most significant post-earnings development, sharpening the portfolio toward high-growth sleep/connected care and freeing capital for an accelerated buyback; FY2026 financial guidance was reiterated in the 8-K.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q4 FY2026 and FY2026 full year are essentially flat since the April 30 post-print baseline — revenue and EPS revisions are within 1% — indicating the street is tracking guidance closely with no meaningful divergence; the gap is neither a risk nor a cushion, leaving the print as the primary catalyst.

Source: Visible Alpha. Baseline as of May 5, 2026 (~5 trading days post Q3 FY2026 earnings on April 30, 2026). All estimates are consensus. Estimate Δ reflects change from post-print baseline to current. The near-zero revision across all KPIs confirms the street is anchored to management's guidance with no meaningful drift in either direction.

5. Stock Performance

Key Takeaway: RMD has lagged both IHI (+5.2%) and the S&P 500 (+7.1%) since the April 30 earnings, rising only +4.8%; the underperformance reflects sentiment drag from the MatrixCare portfolio restructuring and uncertainty around FY2027 guidance, not fundamental deterioration — the stock recovered sharply on the July 7 divestiture announcement before fading again.

RMD vs. IHI (iShares U.S. Medical Devices ETF) vs. S&P 500 (SPY) — Indexed to 100 at April 30, 2026 earnings date. Source: Stock Price Data.

Key observations: (1) RMD sold off ~13% from the post-earnings level through early June, underperforming IHI and SPY, driven by investor uncertainty around RCS portfolio management and competitive concerns. (2) The stock recovered sharply in late June/early July on the MatrixCare divestiture announcement ($490M, July 7), which was received positively as a portfolio-sharpening move. (3) Post-divestiture, RMD has traded sideways to slightly lower, suggesting the market is waiting for the FY2027 guidance framework on the August 6 call before re-rating. (4) IHI used as the sector ETF — appropriate given RMD’s classification as a U.S.-listed medical device company focused on sleep and respiratory care.

6. Material News & Developments

Key Takeaway: The MatrixCare divestiture for $490M (announced July 7) is the most consequential development since the Q3 print — it removes ~$220M of lower-margin RCS revenue from the FY2027 base and funds an accelerated buyback, but also requires management to deliver a credible FY2027 bridge on the August 6 call.

• July 7, 2026 — MatrixCare Divestiture Announced (8-K): ResMed entered a definitive agreement to sell MatrixCare (skilled nursing, senior living, home health/hospice software) to Frazier Healthcare Partners for $490M all-cash. MatrixCare generated ~$220M revenue and ~$55M non-GAAP operating profit in FY2026. Brightree (U.S.) and MEDIFOX DAN (Germany) are retained. Proceeds earmarked for accelerated share repurchase (ASR) program. Transaction expected to close in Q1 FY2027 (calendar Q3 2026), subject to regulatory approval. TSAs to offset stranded costs in Year 1.
• Implication: Removes a lower-growth, lower-margin business; sharpens focus on sleep/connected care; ASR is incremental to the >$800M FY2027 buyback commitment. Market will want to see the FY2027 revenue/EPS bridge on August 6.
• June 30, 2026 — Q4 FY2026 Earnings Date Confirmed: ResMed confirmed August 6, 2026 as the Q4 FY2026 earnings date. Management indicated FY2027 full-year outlook will be provided on this call.
• June 1, 2026 — Noctrix Health Acquisition Closed: ResMed completed the ~$340M acquisition of Noctrix Health (Nidra RLS device for restless leg syndrome). Noctrix expected to contribute ~$30M revenue and reduce non-GAAP EPS by ~$0.20 in FY2027. Management frames Noctrix as a platform for noninvasive nerve stimulation (RLS, PTSD, depression, insomnia) — not just a single-product tuck-in.
• Implication: Modest near-term EPS dilution; higher-margin, faster-growing asset. Expands addressable market into adjacent sleep disorders with shared prescriber/distribution channel.
• May 19, 2026 — Oura Ring Strategic Partnership Announced: ResMed announced a formal strategic alliance with Oura enabling Oura Ring members who detect elevated nighttime breathing disturbances to be directed into ResMed’s sleep health education and care pathway. Oura is pursuing an IPO. Management also cited Whoop, Garmin, and Google Fitbit as part of the broader wearable-to-clinical funnel.
• Implication: Shifts wearable partnerships from passive ecosystem integrations to active patient referral pipelines; top-of-funnel demand generation that could accelerate CPAP starts over time.
• May 19, 2026 — William Blair Growth Stock Conference: ResMed participated in the 46th Annual William Blair Growth Stock Conference. Management reiterated capital return escalation (>$200M/quarter buybacks in Q4 FY2026, >$800M for FY2027) and expanded the wearable funnel narrative.
• April 30, 2026 — Q3 FY2026 Earnings (Most Recent Print): Revenue $1,431.4M (+8.3% YoY, slight beat); non-GAAP EPS $2.86 (beat). Gross margin expanded meaningfully YoY and sequentially. CFO Brett Sandercock retirement announced; Aaron Bloomer (formerly Exact Sciences) named successor. AirCurve 11 COPD launch highlighted. New fabric mask clinical data (AirTouch N30i) showed higher 90-day compliance vs. silicone equivalent.

7. Peer Commentaries — Q4 FY2026 Read-Throughs (Last 60 Days)

Key Takeaway: The most relevant peer read-throughs for RMD’s Q4 FY2026 print come from Inspire Medical (INSP) and Eli Lilly (LLY); INSP’s reimbursement disruption is RMD-specific negative (CPAP demand beneficiary), while LLY’s Retatrutide OSA data pipeline is a longer-term watch item rather than a near-term headwind.

Note: Only peer commentary from the current reporting period (Q4 FY2026, calendar Q2 2026) or post-Q3 FY2026 earnings (after April 30, 2026) is included below. Prior-quarter earnings commentary has been excluded.

Inspire Medical Systems (INSP) — Q2 CY2026 Earnings Call, August 3, 2026

Relevance to RMD: HIGH. INSP is the primary alternative sleep apnea therapy (hypoglossal nerve stimulation) and competes for the same OSA patient pool. INSP’s results are a direct read-through on sleep apnea market dynamics, CPAP demand, and GLP-1 impact.

• INSP revenue declined 7.6% YoY to $200.6M in Q2 CY2026, primarily due to coding and reimbursement disruption (C-code changes, Wiser program). Full-year adverse impact estimated at $120–$130M.
• Read-through for RMD: INSP’s reimbursement disruption is specific to implantable HNS therapy, not CPAP. CPAP/PAP therapy is unaffected by these coding changes. INSP’s difficulties may actually redirect some OSA patients toward CPAP, a modest positive for RMD device demand.
• GLP-1 commentary: INSP management stated GLP-1s will be a “long-term benefit” to help patients lose weight and qualify for Inspire therapy, and do not expect GLP-1s to “change overall demand for Inspire therapy.” INSP sees increasing prior authorizations and believes GLP-1s are net positive long-term.
• Read-through for RMD: Consistent with RMD’s own GLP-1 narrative (higher CPAP start rates, higher resupply rates for GLP-1 patients). Both companies are framing GLP-1s as demand tailwinds, not headwinds.
• CMS 2027 proposed reimbursement: CMS proposed increasing hospital outpatient reimbursement for Inspire five procedure to $35,414 (+12% vs. 2026) and ASC reimbursement to $31,722 (+15%). Physician fee schedule proposed at ~$699 (-4% YoY).
• Read-through for RMD: Favorable reimbursement environment for sleep apnea procedures broadly supports the HME/DME channel that distributes CPAP. No direct CPAP reimbursement change signaled.
• International strength: INSP noted “International had a very good Q2” with growth primarily in continental Europe (Germany, Austria, Switzerland, Netherlands, Belgium, France post-reimbursement). Japan and Singapore also contributing.
• Read-through for RMD: Positive signal for RMD’s ROW segment, which consensus expects at $430M (+10.6% YoY). European sleep market appears healthy.
• Project Horizon restructuring: INSP announced a strategic growth plan to create $30M of annualized investment capacity, with $20–25M in pre-tax restructuring charges (~90% in Q3 CY2026). Supply chain consolidation underway.
• Read-through for RMD: Neutral for RMD. INSP’s restructuring is company-specific and reflects its own reimbursement challenges, not a market-wide signal.

Eli Lilly (LLY) — Q2 CY2026 Earnings Call, August 5, 2026

Relevance to RMD: MEDIUM. LLY is the leading GLP-1 manufacturer. GLP-1 adoption is a key debate for RMD — management has consistently framed it as a tailwind (higher CPAP starts, higher resupply). LLY’s pipeline commentary on OSA is a longer-term watch item.

• Retatrutide Phase 3 OSA data: LLY announced positive results from three Phase 3 Triumph trials (obesity, T2D+obesity, severe obesity+CVD). The clinical data package now supports global registrations in obesity, obstructive sleep apnea, and knee osteoarthritis pain. LLY plans to submit for U.S. approval in Q1 2027 under BLA pathway. First OSA readout for Fonio (oral GLP-1) expected later in 2026.
• Read-through for RMD: Longer-term watch item. A GLP-1 approved specifically for OSA could theoretically reduce CPAP demand at the margin, but RMD’s own real-world data shows GLP-1 patients have ~10% higher CPAP start rates and meaningfully higher resupply rates. The two therapies appear complementary rather than substitutive in practice. No near-term impact on Q4 FY2026.
• GLP-1 market scale: Mounjaro and Zepbound combined for $14.9B in Q2 2026 revenue (+$6.3B YoY). Total U.S. incretin analog market prescriptions grew 31% YoY. Anti-obesity total prescriptions grew 78% in Q2.
• Read-through for RMD: Accelerating GLP-1 adoption at scale supports RMD’s thesis that GLP-1 patients are entering the sleep health funnel at higher rates. The larger the GLP-1 patient population, the larger the potential CPAP demand tailwind over time.

Philips (PHG) — Q2 CY2026 Earnings Call, July 28, 2026

Relevance to RMD: LOW-MEDIUM. Philips exited the CPAP market following its recall and is no longer a direct competitor in sleep devices. However, PHG’s commentary on broader healthcare market dynamics and hospital-at-home trends is contextually relevant.

• Sleep and respiratory care: PHG reported low single-digit growth in its Sleep and Respiratory Care segment, primarily led by Europe and Japan. No specific CPAP commentary (PHG exited the market).
• Read-through for RMD: Minimal direct read-through. PHG’s sleep segment is residual/legacy; not a competitive signal for RMD.
• Hospital-at-home trend: PHG highlighted Karolinska University Hospital selecting a PHG-led consortium for Stockholm’s first region-wide hospital-at-home program (capacity for 15,000 patients annually). North America showing healthy patient volumes and procedural growth.
• Read-through for RMD: Positive for RMD’s connected home-based care strategy. Growing hospital-at-home adoption supports the structural shift toward home-based respiratory care that underpins RMD’s long-term growth thesis.
• China market: PHG noted continued challenging conditions in China health systems due to centralized procurement expansion and subdued hospital investment. Personal health broadly stable.
• Read-through for RMD: Modest negative watch item for RMD’s ROW device segment, though RMD’s China exposure is smaller relative to PHG’s.

AstraZeneca (AZN) — Q2 CY2026 Earnings Call, July 27, 2026

Relevance to RMD: LOW. AZN’s respiratory portfolio (Fasenra, Tezspire, Breztri) targets severe asthma and COPD with biologics — different mechanism and patient population from CPAP. However, AZN’s COPD pipeline commentary is contextually relevant given RMD’s AirCurve 11 COPD launch.

• COPD pipeline: AZN highlighted “highly clinically meaningful benefits” from Oberon and Titania Phase 3 trials for tocilizumab in COPD. Plans to present at European Respiratory Society Congress in September. Also advancing inhaled TSLP (Phase 2 readout) and TC 3721 (inhaled PDE3/4 inhibitor, Phase 3 in China).
• Read-through for RMD: Neutral to slightly positive. Growing COPD treatment options (biologics, inhaled therapies) expand the overall COPD patient management ecosystem. RMD’s AirCurve 11 targets COPD patients who need bilevel/NIV support — a different and complementary intervention to AZN’s biologics.
• Oral GLP-1 (Olecko) Phase 3 initiation: AZN initiated Phase 3 for its oral GLP-1 molecule in obesity and T2D. Phase 2 showed up to 11.8% weight loss at 36 weeks. Plans include OSA and heart failure indications.
• Read-through for RMD: Same as LLY read-through — longer-term watch item; near-term neutral. More GLP-1 entrants expand the obesity treatment market, which RMD views as a CPAP demand tailwind.

8. Insider Transaction Activity

Key Takeaway: No open-market buys; all CEO transactions are routine 10b5-1 planned sales (option exercise + same-day sale, consistent cadence of ~4,991 shares monthly). One discretionary tax-withholding transaction by the General Counsel. Nothing unusual — no clustered discretionary selling or buying signal.

Source: SEC Form 4 filings. Open-market buys and sells only (Form 4 codes P/S) plus 10b5-1 plan transactions. CEO Farrell’s transactions are all pre-planned option exercises with same-day sales under a 10b5-1 plan — identical structure and share count (~4,991 shares) each month, consistent with a systematic liquidation program and carrying no informational signal. The General Counsel’s F-code transaction is a mandatory tax withholding on vesting, not a discretionary sale. No open-market buys or discretionary sales were filed in the period. Insider activity is unremarkable heading into the print.